​

23andMe (ME) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

ME Stock Forecast

23andMe (ME) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $3.71, with a high of $7.00 and a low of $0.42. This represents a 508.20% increase from the last price of $0.61.

- $1 $2 $3 $4 $5 $6 $7 High: $7 Avg: $3.71 Low: $0.42 Last Closed Price: $0.61

ME Stock Rating

23andMe stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (75.00%), 1 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 1 3 Strong Sell Sell Hold Buy Strong Buy

ME Price Target Upside V Benchmarks

TypeNameUpside
Stock23andMe508.20%
SectorHealthcare Stocks 15.45%
IndustryDiagnostics & Research Stocks8.42%

Price Target Trends

1M3M12M
# Anlaysts---
Avg Price Target---
Last Closing Price$0.61$0.61$0.61
Upside/Downside---
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jun, 25----11
Apr, 25----11
Mar, 25----11
Feb, 25----11
Jan, 25----11
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 16, 2024Daniel GrosslightCitigroup$0.42$0.3423.53%-31.15%
Nov 29, 2022Berenberg Bank$7.00$2.76153.62%1047.54%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 16, 2024CitigroupNeutralNeutralhold
May 28, 2024CitigroupNeutralNeutralhold
May 24, 2024Cowen & Co.BuyBuyhold
Apr 15, 2024CitigroupNeutralNeutralhold

Financial Forecast

EPS Forecast

$-30 $-25 $-20 $-15 $-10 $-5 Mar 22 Mar 23 Mar 24 Mar 25 Mar 26 Mar 27
Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27
Reported$-9.96$-13.81$-27.59---
Avg Forecast$-10.47$-13.57$-22.48$-12.59$-10.64$-7.80
High Forecast$-10.47$-13.57$-22.48$-12.59$-10.64$-7.80
Low Forecast$-10.47$-13.57$-22.48$-12.59$-10.64$-7.80
Surprise %-4.87%1.77%22.73%---

Revenue Forecast

$150M $180M $210M $240M $270M $300M Mar 22 Mar 23 Mar 24 Mar 25 Mar 26 Mar 27
Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27
Reported$271.89M$299.49M$219.64M---
Avg Forecast$275.63M$298.41M$211.43M$166.68M$198.42M$251.39M
High Forecast$275.63M$298.41M$217.50M$166.68M$198.42M$251.39M
Low Forecast$275.63M$298.41M$205.35M$166.68M$198.42M$251.39M
Surprise %-1.36%0.36%3.88%---

Net Income Forecast

$-5B $-4B $-3B $-2B $-1B $0 Mar 22 Mar 23 Mar 24 Mar 25 Mar 26 Mar 27
Mar 22Mar 23Mar 24Mar 25Mar 26Mar 27
Reported$-217.49M$-311.66M$-666.70M---
Avg Forecast$-4.98B$-322.85M$-534.95M$-299.60M$-253.22M$-185.67M
High Forecast$-4.98B$-322.85M$-534.95M$-299.60M$-253.22M$-185.67M
Low Forecast$-4.98B$-322.85M$-534.95M$-299.60M$-253.22M$-185.67M
Surprise %-95.64%-3.47%24.63%---

ME Forecast FAQ

Is 23andMe stock a buy?

23andMe stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that 23andMe is a favorable investment for most analysts.

What is 23andMe's price target?

23andMe's price target, set by 4 Wall Street analysts, averages $3.71 over the next 12 months. The price target range spans from $0.42 at the low end to $7 at the high end, suggesting a potential 508.20% change from the previous closing price of $0.61.

How does 23andMe stock forecast compare to its benchmarks?

23andMe's stock forecast shows a 508.20% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the diagnostics & research stocks industry (8.42%).

What is the breakdown of analyst ratings for 23andMe over the past three months?

  • June 2025: 0% Strong Buy, 0% Buy, 0% Hold, 0% Sell, 100.00% Strong Sell.
  • April 2025: 0% Strong Buy, 0% Buy, 0% Hold, 0% Sell, 100.00% Strong Sell.
  • March 2025: 0% Strong Buy, 0% Buy, 0% Hold, 0% Sell, 100.00% Strong Sell.

What is 23andMe’s EPS forecast?

23andMe's average annual EPS forecast for its fiscal year ending in March 2025 is $-12.59, marking a -54.37% decrease from the reported $-27.59 in 2024. Estimates for the following years are $-10.64 in 2026, and $-7.8 in 2027.

What is 23andMe’s revenue forecast?

23andMe's average annual revenue forecast for its fiscal year ending in March 2025 is $166.68M, reflecting a -24.11% decrease from the reported $219.64M in 2024. The forecast for 2026 is $198.42M, and $251.39M for 2027.

What is 23andMe’s net income forecast?

23andMe's net income forecast for the fiscal year ending in March 2025 stands at $-300M, representing a -55.06% decrease from the reported $-667M in 2024. Projections indicate $-253M in 2026, and $-186M in 2027.